Quantitative gene expression of two types of glycine transporter in the rat central nervous system

Cerebral metabolic effects of intravenous glycine in healthy human subjects

Enhancing N-methyl-D-aspartate (NMDA) receptor function via increasing synaptic concentrations of glycine is currently investigated as a novel approach to treat schizophrenia. The neural correlates of enhanced NMDA receptor function in humans, however, are unclear to date. The present study determines the effects of intravenous administration of the glycine on regional cerebral metabolic rate of glucose (rCMRGlu) in healthy control subjects by using [18F]fluorodeoxyglucose and positron emission tomography and on neuropsychological behavioral measures. Thirteen healthy volunteers were recruited, and 12 subjects completed the protocol. These individuals participated in 1 magnetic resonance imaging study and 2 [18F]fluorodeoxyglucose positron emission tomography studies. In a double-blind, randomized, controlled, crossover design, participants received on one test day an intravenous glycine infusion and on the other test day a placebo infusion. There were no significant behavioral and neuropsychological effects of glycine compared with placebo. However, there was a significant reduction of whole-brain CMRGlu during administration of glycine compared with placebo (t = 2.60, df = 11, P = 0.023). In the a priori-selected regions of interest, there was a significant reduction in the cerebellum (t = -3.18, df = 11, P = 0.009) and the dorsolateral prefrontal cortex (t = -2.31, df = 11, P = 0.041). When corrected for whole-brain CMRGlu, rCMRGlu differences were not significant. This study suggests that studies of whole-brain cerebral metabolism may be useful for studying glycine-related mechanisms in healthy humans because there is not a clear cognitive or behavioral signal related to glycine administration at doses thought to be important clinically in patient populations.

Pharmacological properties of glycine uptake in the developing rat retina

A pharmacological characterization of glycine transport was performed in the rat retina at different postnatal ages. The uptake of 3H-glycine increased during the first 2 weeks of postnatal age, reaching maximum values at 12 days; then it decreased sharply to the adult values. We found a Na+ -dependent and high-affinity transport system with a Km of 100 microM. The Na+ Hill coefficient for glycine uptake was 1.76 +/- 0.07. Although glycine uptake was insensitive to staurosporine and phorbol ester, it was reduced 40-50% by sarcosine and ALX5407. Besides, amoxapine inhibited glycine uptake by 40 and 70% in adult and immature retina, respectively. These results suggest that the Glyt1 transporter was concentrated in the nerve terminals. In addition to the presence of Glyt1 in the retina, our results provided evidence of the occurrence of Glyt2 and/or another isoform of glycine transporter, which might have had a role in the retina development.

An immunocytochemical study on specific amacrine cell subpopulations in the rat retina after ischemia

Transient retinal ischemia leads to the loss of neurons in the inner retina. In an accompanying paper [F. Dijk, S. Van Leeuwen, W. Kamphuis, Differential effects of ischemia/reperfusion on amacrine cell subtype-specific transcript levels in the rat retina, Brain Res., 1026 (2004) 194-204] we present the results of a study on the effects of experimentally induced retinal ischemia on transcript levels of genes expressed by distinct subpopulations of amacrine cells. In response to 60-min ischemia, three different patterns of changes in transcript levels were found, indicating a differential vulnerability of amacrine subtypes: (i) a gradual decrease of transcript level without recovery (parvalbumin; PV); (ii) a gradual decrease, with varying rates and degrees, followed by partial recovery after 72 h of reperfusion (choline acetyltransferase (ChAT), calretinin (CR) and glycine transporter (Glyt1)); (iii) no significant changes (substance P (SP)). In order to verify whether the degree of cell loss can be predicted from the quantified alterations in gene expression level, immunocytochemical stainings were carried out. A 60-min ischemic period was administered to the rat eye by raising the intraocular pressure, followed by a reperfusion period lasting between 2 h and 4 weeks. Cryosections were immunostained for Glyt1, PV, ChAT, CR, and SP. Double-labelling with apoptosis marker TUNEL was used to demonstrate cell type-specific apoptosis. Following ischemia, the numbers of detected PV-, Glyt1, ChAT-, and CR-immunopositive somata showed a substantial, but differential, reduction at 1-4 weeks after ischemia. The total amount of immunoreactivity present in the inner plexiform layer (IPL) also decreased. The extent of alterations derived from immunocytochemical staining was greater than was anticipated from the decrease of transcript levels. Only for SP, no significant decrease in number of cells or in the intensity of immunoreactivity in IPL was observed, which is in agreement with the absence of significant changes in transcript levels. In conclusion, retinal ischemia/reperfusion differentially affects amacrine cell populations. Although both protein and mRNA levels are reduced, transcript levels are less attenuated. Caution must be applied in the use of real-time quantitative PCR (qPCR) screening as a tool to assess the cellular pattern of neurodegeneration in the retina.

Pharmacological properties of glycine transport in the frog retina

The high-affinity glycine transport in neurons and glial cells is the primary means for inactivating synaptic glycine. Two different glycine transporter genes, Glyt-1 and Glyt-2, have been cloned. Glyt-1 has been reported to occur in the retina, but there is no evidence for expression of the Glyt-2 transporter. We have pharmacologically characterized glycine transport in the frog retina. 3H-Glycine uptake in the retina was insensitive to modulation by phorbol esters or changes in cAMP levels, and was partially inhibited by sarcosine. Differential sensitivity of glycine transport to sarcosine was exhibited by synaptosomal fractions from the inner and outer plexiform layers of the frog retina. The Na+ Hill coefficient of glycine uptake was 2.0, as has been reported for Glyt-2. In addition, amoxapine, a specific inhibitor of the Glyt-2a isoform, reduced by 60% glycine uptake by P2 synaptosomal fraction. Our results indicate the presence of different glycine transporter isoforms in the frog retina, acting mainly through the classical inhibitory glycine system.

Chromosomal proteins HMGN3a and HMGN3b regulate the expression of glycine transporter 1

HMGN proteins promote chromatin unfolding, enhance access to nucleosomes, and modulate transcription from chromatin templates. It is not known whether they act indiscriminately as general modulators of transcription or whether they regulate specific gene expression. Here, we investigated the role of HMGN3, a recently discovered HMGN family member, in transcription in vivo. We created cell lines overexpressing HMGN3a or its splice variant, HMGN3b, and analyzed their gene expression profiles using microarrays and reverse transcriptase PCR. We found that ectopic expression of HMGN3a alters the expression of approximately 0.8% of genes. Both HMGN3a and HMGN3b upregulate the expression of the glycine transporter 1 gene (Glyt1). Glyt1 encodes a membrane transporter that regulates the glycine concentration in synaptic junctions. Both GLYT1 and HMGN3 are highly expressed in glia cells and the eye, and we show that both proteins are coexpressed in the retina. Chromatin immunoprecipitation assays showed that HMGN3 protein is recruited to a region of the Glyt1 gene encompassing the Glyt1a transcriptional start site. These results suggest that HMGN3 regulates Glyt1 expression and demonstrate that members of the HMGN family can regulate the transcription of specific genes.

Transporters in the neurohypophysial neuroendocrine system, with special reference to vesicular glutamate transporters (BNPI and DNPI): a review

Recent advances in gene technology have helped to identify novel proteins and allowed study of their distribution and functions in the mammalian brain. One class of these proteins is that of transporters, which exist in plasma and organellar membranes of neurons and other cells to move substances selectively across membranes. These transporters can be categorized further into subclasses by their structural property, substrate selectivity, and site of action. Some of them have been identified in the hypothalamus, which is the only brain site where a neural signal is converted to a humoral one, namely, a hormone for a target organ. This unique neural mechanism has long attracted attention as the neuroendocrine system, part of which has been extensively studied as the hypothalamic-neurohypophysial system involved in secretion of vasopressin and oxytocin. However, transporters in this system have been less well studied. A morphological examination of novel transporters would give us cues to a better understanding of the neuronal organization and function of the system. In this review, we first summarize recent findings on expression of transporter gene and immunoreactivity in the hypothalamus. In the second part, we explain our observations on two vesicular glutamate (inorganic phosphate) transporters (BNPI and DNPI) in the supraoptic and paraventricular nuclei and neurohypophysis. Further study of these and other transporters will provide a basis on which to reevaluate the organization and function of the hypothalamic-neurohypophysial system.

Transient down-regulation of NMDA receptor subunit gene expression in the rat retina following NMDA-induced neurotoxicity is attenuated in the presence of the non-competitive NMDA receptor antagonist MK-801

Excitotoxic challenge has been thought to directly target NMDA-receptive neurons to undergo cell death. Recent evidence suggests that NMDA induced cell death is a selective process and that the specificity may be determined by the subunit composition of the NMDA receptor. Using a rat retinal model, we examined the effects of NMDA induced neurotoxicity on the regulation of NMDA receptor subunit gene and protein expression levels to determine if excitotoxic challenge preferentially regulates one or more of the NMDA receptor subunits. Following NMDA insult, the mRNA levels for NR1(com ), NR2A, NR2B and, to a lesser extent, the NR2C subunit were substantially reduced within 24 hr post-treatment (PT), and remained depressed for up to 48 hr. Levels for NR2D, although initially suppressed as early as 6 hr-PT, were least affected by NMDA insult and showed almost full recovery by 48 hr. By 10 days, the levels of gene expression for all five subunits recovered to levels that were indistinguishable from sham treated and untreated retinas. Co-administration of MK-801 with NMDA suppressed the effects of NMDA-induced down-regulation of all five genes. Protein levels for NR1(com ), NR2A and NR2B were also monitored at select time points following NMDA-insult. By 2 days-PT, protein levels for the three subunits were dramatically reduced. By day 10, the levels of protein expression for NR1(com)and NR2B remained suppressed despite the rise in gene expression for these two subunits, whereas protein for NR2A showed a substantial rise in expression. Of the five genes assayed, NR2A and NR2B showed the greatest reduction in expression following NMDA treatment, suggesting that one or both of these subunit may signal events leading to neuronal cell death in the retina. Conversely, gene expression of the NR2D subunit was least affected by NMDA exposure. In view of the evidence that the NR2D subunit is expressed by rod bipolar cells in the rat and that these neurons do not die following NMDA insult, it appears that inclusion of this subunit into functional receptors may provide protection against NMDA-induced cell death. Although the significance of the transient down-regulation of four out of the five NMDA receptor subunits is still not fully understood, the recovery of expression of these genes by day 10-PT indicates that not all of the NMDA receptive neurons are susceptible to NMDA-induced cell death. The preferential down-regulation of the NR2A and NR2B receptor subunits may implicate these subunits as key players in mediating the excitotoxic signal in the retina and possibly elsewhere in the brain.

NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A

Electrophysiological recordings have shown NMDA receptors to be heterogenous structures capable of responding to selected antagonists and agonists in multiple ways. This diversity in functional response has led investigators to conclude that these channels are comprised of unique combinations of receptor subunits which determine a cell's functional NMDA-signature [H. Meguro, H. Mori, K. Araki, E. Kushiya, T. Kutsuwada, M. Yamazaki, T. Kumanishi, M. Arakawa, K. Sakimura, M. Mishina, Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs, Nature (London) 357 (1992) 70-74; T. Ishii, K. Moriyoshi, H. Sugihara, K. Sakurada, H. Kadotani, M. Yokoi, C. Akazawa, R. Shigemoto, N. Mizuno, S. Nakanishi, Molecular characterization of the family of the N-methyl-d-aspartate receptor subunits, J. Biol. Chem. 268 (1993) 2836-2843; K.A. Wafford, C.J. Bain, B. Le Bourdelles, P.J. Whiting, J.A. Kemp, Preferential co-assembly of recombinant NMDA receptors composed of three different subunits, NeuroReport 4 (1993) 1347-1349; T. Priestley, P. Laughton, J. Myers, B. Le Bourdelles, J. Kerby, P.J. Whiting, Pharmacological properties of recombinant human N-methyl-d-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fiberblast cells, Mol. Pharmacol. 48 (1995) 841-848; P.H. Seeburg, N. Burnashev, G. Kohr, T. Kuner, R. Sprengel, H. Monyer, The NMDA receptor channel: molecular design of a coincidence detector, Recent Prog. Horm. Res. 50 (1995) 19-34; A.L. Buller, D.T. Monagahan, Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes, Eur. J. Pharmacol. 320 (1997) 87-94]. In situ hybridization and immunocytochemical studies have shown that there is a spatio-temporal level of expression throughout the brain for each of the receptor subunits with some regions showing a strong preference for a particular subunit. Although these studies collectively show that there are regional differences with respect to NMDA receptor subunit expression in the brain, it has not been determined at what level(s) these genes are expressed or whether each region displays a unique NMDA-subunit signature. The present study was undertaken to examine the level of gene expression for the NR1, NR2A, NR2B, NR2C, NR2D and NR3A receptor subunits in isolated regions of rat brain using the nuclease protection assay. Results show that each of the brain regions examined expresses all six NMDA receptor subunits. The level of message expression for NR1 greatly exceeded that of the other subunits combined, with values ranging from 67-88% of the total subunit gene expression. The relative proportions of the other subunits (NR2A-D and NR3A) varied widely, suggesting that NMDA receptor composition is unique to each region of the brain.